Interestingly, we found that the CF drug Trikafta (VX-661, VX-445, and VX-770) improved the cell surface expression of R75Q- or M470V-CFTR CFTR and suppressed the excessive proinflammatory cytokine production. This evidence concerns the gene CFTR and cystic fibrosis.